Related Experiment Video
Updated: Jun 26, 2026
12:48
In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
Weight loss in neurodegenerative disorders
N A Aziz1, M A van der Marck, H Pijl
1Department of Neurology, Leiden University Medical Centre, Albinusdreef 2, Leiden, The Netherlands. N.A.Aziz@lumc.nl
Journal of Neurology
|January 24, 2009
Summary
Unintended weight loss is common in neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's. Early recognition and interventions to increase energy intake can improve quality of life, though further research is needed.
Area of Science:
- Neurology
- Gerontology
- Metabolism
Background:
- Unintended weight loss is a significant complication in neurodegenerative disorders, increasing morbidity and mortality.
- This issue affects major conditions including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Purpose of the Study:
- To review the characteristics of unintended weight loss in Alzheimer's, Parkinson's, and Huntington's diseases.
- To highlight the importance of recognizing complex pathophysiological processes driving weight loss.
- To discuss potential therapeutic strategies for managing weight loss in these conditions.
Main Methods:
- Review of existing literature on unintended weight loss in Alzheimer's, Parkinson's, and Huntington's diseases.
- Analysis of the common pathophysiological mechanisms underlying weight loss.
- Examination of current and potential treatment approaches.
Main Results:
- Weight loss in these neurodegenerative diseases shares a complex pathophysiology.
- Increasing energy intake is a primary treatment strategy.
- Potential therapeutic targets include systemic energy homeostasis and gastrointestinal function.
Conclusions:
- Timely recognition of the causes of weight loss is crucial for effective management.
- Tailored treatments, primarily focused on increasing energy intake, can improve quality of life.
- Further clinical validation is required for interventions targeting energy homeostasis and gastrointestinal function.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...